154 related articles for article (PubMed ID: 34347212)
1. Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer.
Lorona NC; Cook LS; Tang MC; Hill DA; Wiggins CL; Li CI
Cancer Causes Control; 2021 Dec; 32(12):1375-1384. PubMed ID: 34347212
[TBL] [Abstract][Full Text] [Related]
2. Alcohol, Smoking, and Risks of Breast Cancer Recurrence and Mortality among Women with Luminal, Triple-Negative, and HER2-Overexpressing Breast Cancer.
Loroña NC; Othus M; Malone KE; Linden HM; Tang MC; Li CI
Cancer Epidemiol Biomarkers Prev; 2024 Feb; 33(2):288-297. PubMed ID: 38019269
[TBL] [Abstract][Full Text] [Related]
3. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
4. Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women.
Chen L; Li CI; Tang MT; Porter P; Hill DA; Wiggins CL; Cook LS
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1297-304. PubMed ID: 27307466
[TBL] [Abstract][Full Text] [Related]
5. Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population.
Chen L; Chubak J; Boudreau DM; Barlow WE; Weiss NS; Li CI
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1603-1610. PubMed ID: 28807926
[No Abstract] [Full Text] [Related]
6. Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer.
Lorona NC; Cook LS; Tang MC; Hill DA; Wiggins CL; Li CI
Horm Cancer; 2019 Jun; 10(2-3):71-76. PubMed ID: 30989580
[TBL] [Abstract][Full Text] [Related]
7. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population.
Abubakar M; Sung H; Bcr D; Guida J; Tang TS; Pfeiffer RM; Yang XR
Breast Cancer Res; 2018 Sep; 20(1):114. PubMed ID: 30227867
[TBL] [Abstract][Full Text] [Related]
9. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
10. Locoregional recurrence by molecular subtype after multicatheter interstitial accelerated partial breast irradiation: Results from the Pooled Registry Of Multicatheter Interstitial Sites research group.
Anderson BM; Kamrava M; Wang PC; Chen P; Demanes DJ; Hayes JK; Kuske RR
Brachytherapy; 2016; 15(6):788-795. PubMed ID: 27743957
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
14. Alcohol, smoking, and risk of Her2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer.
Baglia ML; Cook LS; Mei-Tzu C; Wiggins C; Hill D; Porter P; Li CI
Int J Cancer; 2018 Oct; 143(8):1849-1857. PubMed ID: 29708591
[TBL] [Abstract][Full Text] [Related]
15. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
[TBL] [Abstract][Full Text] [Related]
16. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study.
van Maaren MC; de Munck L; Strobbe LJA; Sonke GS; Westenend PJ; Smidt ML; Poortmans PMP; Siesling S
Int J Cancer; 2019 Jan; 144(2):263-272. PubMed ID: 30368776
[TBL] [Abstract][Full Text] [Related]
17. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
18. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
19. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years.
Li CI; Daling JR; Tang MT; Haugen KL; Porter PL; Malone KE
JAMA Intern Med; 2013 Sep; 173(17):1629-37. PubMed ID: 23921840
[TBL] [Abstract][Full Text] [Related]
20. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
